Defective thrombus formation in mice lacking coagulation factor XII
By T. Renné, M. Požgajová, S. Grüner, K. Schuh, H. Pauer, P. Burfeind, D. Gailani, B. Nieswandt. Journal of Experimental Medicine, 2005
731 citations recorded by the source corpus.
Blood coagulation is thought to be initiated by plasma protease factor VIIa in complex with the membrane protein tissue factor. In contrast, coagulation factor XII (FXII)–mediated fibrin formation is not believed to play an important role for coagulation in vivo. We used FXII-deficient mice to study the contributions of FXII to thrombus formation in vivo. Intravital fluorescence microscopy and blood flow measurements in three distinct arterial beds revealed a severe defect in the formation and stabilization of platelet-rich occlusive thrombi. Although FXII-deficient mice do not experience spontaneous or excessive injury-related bleeding, they are protected against collagen- and epinephrine-induced thromboembolism. Infusion of human FXII into FXII-null mice restored injury-induced thrombus formation. These unexpected findings change the long-standing concept that the FXII-induced intrinsic coagulation pathway is not important for clotting in vivo. The results establish FXII as essential for thrombus formation, and identify FXII as a novel target for antithrombotic therapy.
Subfields: Genetics, Hematology
View Paper: https://www.semanticscholar.org/paper/18e79925f8ab7056f040eb2a92f9fadd9c93a055
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- F. Mueller
- N. Mutch
- W. Schenk
- Stephanie A. Smith
- J. Morrissey
- Lucie Esterl
- H. Spronk
- Stefan Schmidbauer
Citations in the corpus
- Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo (2009, positive): “Defective thrombus stability in FXII / mice (Renne et al., 2005a), reports of pulmonary emboli in humans with congenital FXII deficiency (Mangal and Naiman, 1980; Ratnoff et al., 1968), and reduced clot firmness in FXIIa-inhibited blood (Figure 5H) raise an intriguing hypothesis.”